Alumis Inc (ALMS) Stock Forecast & Price Target

Alumis is a clinical-stage biopharmaceutical company that has generated promising phase II and phase III data for its TYK2 inhibitor candidates in some indications, specifically in PsO and SLE. Although the regulatory uncertainty surrounding the future development of SLE may delay potential approval for up to 4 years, its potential approval in PsO presents a solid commercial opportunity in a large market and the company's net cash position adds to its fundamental value. However, potential downward revisions in their estimates and target price could occur if Alumis is unable to differentiate itself from other TYK2 inhibitors or faces challenges in raising additional capital.

Alumis is a clinical-stage biopharmaceutical company focused on developing tyrosine kinase 2 (TYK2) inhibitors for the treatment of psoriasis and systemic lupus erythematosus (SLE). However, the negative outlook by the financial analyst is driven by numerous factors, including uncertainty surrounding the company's pipeline and commercialization risks. The upcoming data on envudeucitinib's safety and NDA submission for psoriasis may not be enough to offset concerns about its potential for success in SLE and other indications. Additionally, the potential competition from established therapies and the need for financing until the company becomes cash flow positive add further risk to the stock. As a result, the analyst has a neutral rating and a 12-month price target of $25 for Alumis's stock.